ByteDance's AI drug unit Anew Labs raises $369m in funding

Anew Labs, the artificial intelligence-focused drug discovery unit spun out from Chinese tech giant ByteDance, has successfully closed a US$369 million funding round, sources said. The completion of the capital raise values the Singapore-incorporated biotech firm at US$1.5 billion, marking a significant validation of its AI-driven approach to pharmaceutical development.

The funding underscores growing investor appetite for companies leveraging artificial intelligence and machine learning to accelerate drug discovery and development processes. Anew Labs has positioned itself at the intersection of technology and life sciences, utilising ByteDance's AI capabilities to identify and develop novel therapeutic compounds more efficiently than traditional methods.

The spinoff was established to operate independently from ByteDance's core social media and technology operations, allowing it to pursue partnerships and funding from global investors and pharmaceutical companies. The successful fundraising round suggests strong confidence among backers in the company's technology platform and commercial prospects in an increasingly competitive biotech landscape.

Anew Labs joins a growing cohort of AI-powered drug discovery companies attracting significant capital investment globally. The biotech sector in Asia has seen expanded investor focus in recent years, with companies in Singapore and the wider region becoming increasingly attractive to venture capital and institutional investors seeking exposure to life sciences innovation.